Redcare Pharmacy N.V. has increased its full-year 2026 revenue guidance for the second time this year, the company announced on September 28, 2026, citing continued strong momentum in prescription (Rx) drug revenue in Germany. The online pharmacy now expects Rx revenue in Germany to reach EUR 730 to 760 million for the full year, up from its previous guidance of EUR 680 to 720 million. This represents growth of 45% to 51%, compared with the earlier forecast of 35% to 43%.
The upgrade follows preliminary figures showing that Rx revenue in Germany grew by 51% year-on-year in September and by 56% in the third quarter. September's performance was particularly notable given the high comparison base from the prior year, when the current Rx bonus was introduced. Total revenue growth guidance for 2026 was also raised to 16% to 18%, from 15% to 17% previously. Non-Rx growth guidance remains unchanged at 10% to 12%, and the adjusted EBITDA margin guidance is confirmed at between 2.5% and 3.0%.
"Our growth is backed by strong customer satisfaction: eRx NPS continues to rise, up 6 points year-on-year to 80 in August," said Olaf Heinrich, CEO of Redcare Pharmacy. While Rx revenue in Germany remained robust throughout the quarter, non-Rx revenue in Germany rebounded well in August and September after a softer July. Based on preliminary figures, the adjusted EBITDA margin remained flat quarter-on-quarter, benefiting from continued operating leverage.
The company will publish its full third-quarter 2026 figures and host its quarterly conference call on October 29, 2026. The revised guidance underscores Redcare's growing role in Europe's digital healthcare market. With over 14 million active customers and more than 500,000 healthcare-related products, the company operates in seven countries: Germany, Austria, France, Belgium, Italy, the Netherlands, and Switzerland. It provides prescription drugs in Germany, Switzerland, and the Netherlands, positioning itself as a one-stop pharmacy.
The raised guidance is significant for investors and the broader pharmacy sector. It signals that demand for online prescription services is accelerating, even as traditional pharmacies face pressure. For Redcare, the strong Rx performance could translate into higher market share and improved profitability. The company's ability to grow Rx revenue by more than 50% year-on-year in Germany, despite a high base, suggests that its digital platform and customer loyalty are gaining traction. The eRx NPS of 80 in August, up 6 points year-on-year, indicates high customer satisfaction, which could drive repeat purchases and referrals.
For the industry, Redcare's success may encourage further investment in telepharmacy and e-prescription infrastructure across Europe. Competitors may need to accelerate their own digital offerings to keep pace. The unchanged EBITDA margin guidance, despite higher revenue, implies that the company is balancing growth with cost discipline, which could reassure investors about sustainable expansion.
Redcare Pharmacy N.V. has been listed on the Frankfurt Stock Exchange (Prime Standard) since 2016 and is part of the SDAX. The original release can be viewed on www.newmediawire.com.
